Get started
Author

Michał Kurlapski

Observed names: M. Kurlapski, Michal Kurlapski
ORCID: 0000-0002-6134-7425
Observed ORCID: 0000-0002-6134-7425
OpenAlex ID: A5031196252
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
2025 · Maria Cristina Pirosa, Alessio Bruscaggin, et al. · Blood · 33
PDF
FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma
2021 · Andrea Gallamini, Michał Kurlapski, et al. · Cancers · 13
PDF
SARS-CoV-2-induced remission of advanced classical Hodgkin lymphoma
2022 · Michał Kurlapski, Grzegorz Romanowicz, et al. · Polskie Archiwum Medycyny Wewnętrznej · 8
PDF
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment—67 Patients Multicenter Analysis
2024 · Grzegorz Charliński, Maximilian Steinhardt, et al. · Cancers · 7
PDF
PIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphoma
2025 · Maciej Szydłowski, Ewa Kurtz, et al. · Cell Death and Disease · 6
PDF
TMAS — Maritime Telemedical Assistance Service at the University Centre of Maritime and Tropical Medicine in Gdynia. The first year activity report
2014 · Michał Kurlapski, Małgorzata Wójcik-Stasiak, et al. · International Maritime Health · 5
PDF
Revisiting the predictive role of 18F‐fluorodeoxyglucose positron emission tomography/computerized tomography on treatment outcome in early‐stage favorable Hodgkin lymphoma
2023 · Andrea Gallamini, Axel Sudria, et al. · Hematological Oncology · 4
PDF
Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy
2025 · Michał Kurlapski, Alicja Braczko, et al. · International Journal of Molecular Sciences · 3
PDF
Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trial
2023 · J. M. Zaucha, M. Picardi, et al. · Hematological Oncology · 3
PDF
Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
2024 · Maria Cristina Pirosa, Matin Salehi, et al. · Blood · 2
Profound neutropenia related to consolidation durvalumab following concurrent radiochemotherapy in III stage non-small-cell lung cancer patient
2021 · Artur Bandura, Michał Kurlapski, et al. · Polskie Archiwum Medycyny Wewnętrznej · 2
PDF
Cukrzyca w społeczeństwie 24/7. Związek między pracą zmianową a zaburzeniami metabolicznymi
2015 · Wojciech Wołyniec, Michał Kurlapski, et al. · Clinical Diabetology · 2
PDF
Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol
2026 · Kateryna Filonenko, Marco Picardi, et al. · Biomedicines · 1
Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial
2025 · Kateryna Filonenko, Marco Picardi, et al. · Blood · 1
357 | A SHORT (x3) NIVOLUMAB BEFORE BGD CHEMOTHERAPY IMPROVES THE REMISSION RATE IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: N‐BURGUND TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP
2025 · J. M. Zaucha, E. Paszkiewicz‐Kozik, et al. · Hematological Oncology · 1
PDF
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
2024 · Matin Salehi, Maria Cristina Pirosa, et al. · Blood · 1
PDF
Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphoma
2023 · M. C. Pirosa, A. Bruscaggin, et al. · Hematological Oncology · 1
PDF
S225: Circulating Tumor Dna Is a Prognostic Biomarker at Baseline and Improves the Accuracy of Interim Pet in Classic Hodgkin Lymphoma
2022 · M. C. Pirosa, A. Bruscaggin, et al. · HemaSphere · 1
Ophelia-like Paraneoplastic Limbic Encephalitis with Haemorrhagic Temporal Lobe Involvement and Cauda Equina Dysfunction in Classical Hodgkin Lymphoma: A Case Report
2026 · Abhishek Singla, Ritu Amit Chhabria, et al. · Hematology Reports
417 | TMTV < THAN 32.5 mL IMPAIRS THE SUCCESSFUL DETECTION OF ctDNA IN EARLY‐STAGE HODGIN LYMPHOMA PATIENTS—THE PRELIMINARY REPORT FROM THE RAFTING TRIAL
2025 · M. M. Bednarek, S. Chauvie, et al. · Hematological Oncology
PDF
Assessment of a nutritional status of patients qualified for autologous and allogeneic heamatopoietic cell transplantation
2024 · S. Czaja-Stolc, M. Dutka, et al. · Clinical Nutrition ESPEN
Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study
2023 · E. Paszkiewicz‐Kozik, M. Kurlapski, et al. · Hematological Oncology
PDF
MEN1703-Mediated PIM Kinases Inhibition Impairs Protumoral and Immunosuppressive Phenotype and Functions of Macrophages in Classical Hodgkin Lymphoma
2022 · Maciej Szydlowski, Filip Garbicz, et al. · Blood
P044: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
2022 · Maciej Szydłowski, Filip Garbicz, et al. · HemaSphere
P050: Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells
2022 · Michał Kurlapski, Maciej Szydłowski, et al. · HemaSphere
Works count: 29
Citation count: 94
H-index: 5
I10-index: 2
Year
Topic
Type